Edison's EPI-743 gets FDA fast track status to treat Friedreich's Ataxia - 1 views
-
Alex Parker on 18 Mar 14US-based Edison Pharmaceuticals has received Fast Track designation from the US Food and Drug Administration (FDA) for its lead drug EPI-743 to treat patients with Friedreich's ataxia.